drugset / Trial / NCT00429923

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

NCT00429923

Phase 3 Completed 219 enrolled Sirion Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Difluprednate Small molecule 0.05 % Other

Indications

No indication recorded.